Pancreatic Cancer Clinical Pipeline | 290+ Companies Advancing the Future of Treatment

The Pancreatic Cancer market is rapidly evolving with cutting-edge research and breakthrough therapies driven by leading companies like TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, and Pionyr Immunotherapeutics. These innovators are revolutionizing treatment approaches and shaping the future of Pancreatic Cancer care, offering new hope for patients worldwide.

DelveInsight's 'Pancreatic Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Pancreatic Cancer therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Pancreatic Cancer pipeline domain.

For emerging Pancreatic Cancer drugs, the Pancreatic Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Pancreatic Cancer Pipeline Report
• DelveInsight's Pancreatic Cancer Pipeline analysis depicts a robust space with 290+ active players working to develop 300+ pipeline drugs for Pancreatic Cancer treatment.
• The leading Pancreatic Cancer companies include ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., and others are evaluating their lead assets to improve the Pancreatic Cancer treatment landscape.
• Key Pancreatic Cancer pipeline therapies in various stages of development include Pamrevlumab, Devimistat, Masitinib, SBP-101, TAS-102, RAIN-32, IMX-110, Mitazalimab, Elraglusib, and others.
• In February 2025, Alligator Bioscience announced the successful completion of its End of Phase 2 (EOP2) interaction with the FDA, paving the way for a Phase 3 trial in 2025. The trial will test mitazalimab as a first-line treatment for metastatic pancreatic cancer in combination with mFOLFIRINOX.
• In February 2025, Alpha Tau Medical Ltd. announced FDA approval of an Investigational Device Exemption (IDE) supplement for its Alpha DaRT® cancer therapy. This approval expands a clinical study, initially approved in January 2025, to include a broader group of pancreatic cancer patients, exploring the combination of Alpha DaRT and first-line chemotherapy.
• In January 2025, the FDA granted Fast Track Designation to LOAd703, an oncolytic adenovirus with transgenes encoding 4-1BBL and TMZ-CD40L, for the potential treatment of pancreatic cancer. LOAd703 is currently being evaluated in the Phase 1/2 LOKON001 trial, assessing its safety and feasibility in combination with chemotherapy for patients with unresectable or metastatic advanced PDAC.
• In January 2025, Elicio Therapeutics, Inc.announced it received supportive feedback from the U.S. FDA in an End of Phase 1 Type B meeting regarding the registrational strategy for ELI-002. Based on the feedback, Elicio plans to file a Biologics License Application (BLA), contingent on results from a planned Phase 3 trial.
• In October 2024, SONIRE Therapeutics announced that its next-generation High-Intensity Focused Ultrasound (HIFU) therapy system has been designated as a breakthrough device by the FDA for treating pancreatic cancer.

Request a sample and discover the recent breakthroughs happening in the Pancreatic Cancer pipeline landscape @ https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pancreatic Cancer Overview
Pancreatic cancer is a malignant disease in which cancerous cells develop in the tissues of the pancreas, a vital organ located behind the lower part of the stomach. The disease commonly originates from pancreatic intraepithelial neoplasia (PanIN), considered the primary pre-neoplastic lesion. However, it can also emerge from larger precursor lesions, such as intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms. Pancreatic cancer is characterized by abnormal autocrine and paracrine signaling, driving cancer cell proliferation, migration, invasion, and metastasis.

Additionally, pancreatic cancer exhibits metabolic irregularities and resistance to growth-inhibitory pathways. One key example is the dysregulated transforming growth factor-beta (TGFβ) signaling, where increased expression of TGFβ isoforms paradoxically enhances tumor progression despite its physiological role as a tumor suppressor. Within the tumor microenvironment, TGFβ exerts paracrine effects that support tumor growth and metastasis. Moreover, it directly stimulates cancer cell proliferation through non-canonical pathways involving mitogen-activated protein kinase (MAPK) phosphorylation, proto-oncogene tyrosine-protein kinase Src (SRC), and AKT phosphorylation. Canonical SMAD4-dependent mechanisms further contribute to tumor progression by upregulating WNT7B expression.

The genetic landscape of pancreatic cancer involves alterations in three key categories: tumor suppressor genes, oncogenes, and DNA mismatch-repair genes. The most common genetic mutations found in pancreatic adenocarcinoma include the activation of the KRAS oncogene and the inactivation of tumor suppressor genes such as CDKN2A, TP53, SMAD4, and BRCA2. In addition, chromosomal losses, gene amplifications, and telomere shortening are frequently observed, further contributing to disease progression.

Systemic therapy, particularly chemotherapy, remains the cornerstone of pancreatic cancer treatment. In certain cases, targeted therapy and immunotherapy are also considered, especially for patients with specific molecular or genetic markers. Treatment approaches may involve a single medication or a combination of drugs administered alongside surgery and/or radiation therapy. Ongoing clinical trials continue to explore novel therapeutic options, with the potential to replace or enhance current treatment standards based on emerging evidence.

Find out more about Pancreatic Cancer medication @ https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pancreatic Cancer Treatment Analysis: Drug Profile
Pamrevlumab: FibroGen
Pamrevlumab is a potential first-in-class antibody being developed by FibroGen that inhibits the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. The U.S. Food and Drug Administration has granted Orphan Drug Designation and Fast Track designation to Pamrevlumab for the treatment of patients with pancreatic cancer. Currently, it is in the Phase III stage of clinical trial evaluation to treat Pancreatic Cancer.

Devimistat: Cornerstone Pharmaceuticals
CPI-613 (devimistat) is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth. Cancer progresses because it utilizes the mitochondria - the energy machinery of the cells - to generate the building blocks of the next tumor in order to fuel cancer growth and proliferation. Because it is designed to be highly specific, minimally toxic and effective against a wide variety of cancers, devimistat can be used for recurrent and hard-to-treat cancers, including on a chronic basis; it may also enhance the sensitivity of cancer cells to other treatment modalities, including chemotherapy. Currently, the drug is in the Phase III stage of its development for treating pancreatic cancer.

Masitinib: AB Science
Masitinib is a highly selective inhibitor of mast cells, which gives therapeutic benefit by impacting on mast cell related remodeling of the tumor microenvironment. Masitinib is being developed in combination with chemotherapies for the treatment of malignancies through its immunotherapeutic properties. The increased mast cell activity within the tumor microenvironment can promote disease progression by releasing numerous pro-tumoral mediators, down-regulating the immune response to tumors, and modulating macrophages towards a pro-tumoral state. The inhibition of the mast cell activity results in an anti-tumor effect.

Key Pancreatic Cancer Therapies and Companies
• Pamrevlumab: FibroGen
• Devimistat: Cornerstone Pharmaceuticals
• Masitinib: AB Science
• SBP-101: Panbela Therapeutics
• TAS-102: Taiho Pharmaceutical Co., Ltd.
• RAIN-32: Rain Oncology
• IMX-110: Immix Biopharma
• Mitazalimab (ADC-1013): Alligator Bioscience
• Elraglusib (9 ING 41): Actuate Therapeutics

Learn more about the novel and emerging Pancreatic Cancer pipeline therapies @ https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pancreatic Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Pancreatic Cancer Pipeline Report
• Coverage: Global
• Key Pancreatic Cancer Companies: ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., and others.
• Key Pancreatic Cancer Pipeline Therapies: Pamrevlumab, Devimistat, Masitinib, SBP-101, TAS-102, RAIN-32, IMX-110, Mitazalimab, Elraglusib, and others.

Dive deep into rich insights for drugs used for Pancreatic Cancer treatment; visit @ https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Pancreatic Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Pancreatic Cancer Pipeline Therapeutics
6. Pancreatic Cancer Pipeline: Late-Stage Products (Phase III)
7. Pancreatic Cancer Pipeline: Late-Stage Products (Phase III)
8. Pancreatic Cancer Pipeline: Mid-Stage Products (Phase II)
9. Pancreatic Cancer Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.